Announced
Synopsis
Xoma Royalty-backed XRA 5, a newly established Delaware corporation, agreed to acquire Mural Oncology, a clinical-stage immuno-oncology company, for $36.2m. "The Transaction Agreement with XOMA Royalty announced today is the result of a thorough and wide-ranging strategic review process, conducted with the support of our legal and financial advisors. We believe that this transaction, which is supported by our Board, achieves the goal of this strategic review process, which was to maximize shareholder value," Caroline Loew, Mural Oncology CEO.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Claim DealAll rights reserved. Copyright © 2025 Datasite
Bidder Team (5)
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy